Phb #022, Απρίλιος 2014

of 84 /84
# 022 ΜΑΡ-ΑΠΡ 2 0 1 4 ΤΙΜΗ 6 www.virus.com.gr ISSN: 2241-0961 Συνέντέυξη Γιώργος Ελευθερίου Προφίλ Άδωνις Γεωργιάδης ρέΠορτάζ Το ΤOP 10 των φαρμάκων που χάνουν δίπλωμα ευρεσιτεχνίας το 2014 ρέΠορτάζ Μειώθηκαν οι αξονικές στη χώρα

Embed Size (px)

description

 

Transcript of Phb #022, Απρίλιος 2014

  • #022- 2 0 1 4 6

    www . v i r u s . c o m . g rI S S N : 2 2 4 1 - 0 9 6 1

    OP 10 2014

  • i d

    2 / 2011

    . 266, 152 32 , .: 210 6882100, www.glaxosmithkline.gr

    GR

    /PH

    CA

    /000

    1/13

  • 1

  • i d

    2 / - 2014

    8 ;

    10

    18 !

    30 Top 10 2014

    18

    8

    40

    #022- 2014

    CEO: [email protected]eu

    : [email protected]

    - : [email protected]

    [email protected]

    [email protected]

    : [email protected]

    : [email protected]

    : [email protected]

    : [email protected]

    30

  • 3

    BestWorkplacesGreece

    2013

    goodto knowyou

  • i d

    4 / - 2014

    44

    52

    38

    44 !

    52

    60

    73 News

    78

    ISSN: 2241-0961

    10

    38

    E - CrEAtIvE: [email protected]

    tmhmA mArkEtINg & m : [email protected]

    - [email protected]

    & : [email protected]

    : [email protected]

    : [email protected]

    : Shutterstock

    - - : Pressious ....

    : ETHOS MEDIA S.A.

    29, 174 56 t: 210 9984950, : 210 9984953 E: [email protected] www.virus.com.gr www.ethosmedia.eu

    * , , ,

    , FSC .

  • 5D:\Molyvi\menarini\eteriki_katahorisi\ETAIRIKI_21X28.cdr, 25 2013 9:01:27

    p p pComposite 150 lpi at 45 degrees

  • E D I T R I A L

    6 / - 2014

    ,

    :

    ,

    ,

    .

    .

    !

    ,

    .

    4

    ,

    ,

    ,

    .

    .

    , ,

    ,

    .

    .

    ,

    ,

    ,

    ,

    !

    .

    ,

    ,

    .

    ,

    .

    ,

  • 7C

    M

    Y

    CM

    MY

    CY

    CMY

    K

    demo_ktx_tel_21x28.pdf 1 4/11/14 2:46 PM

  • 8 / - 2014

    ! - ! , ,

    . -, . , -, , - , - .

    ... - . , , -, , -, .

    , , - . - , , - -, - . .

    , - - - - - .

    - , - . -

    TV,

    !

    ;

    , .

    . - -, -, , .

    , - . , , -, , , - !

    : - , - - -, . , - , , , !

    , , -, - .

    , , - . , , - TV - - - - !

    , - , , -

  • 9: ' .

    18 , . , -. , , (..: ), - - - .

    - - , - .

    , , - 42 , - , . - , , .

    - , PhB, - - .

    , . 7 - - - !

    , , Twitter, - . - - , - , .

    - ; , -

    . : - - , .

    , - -, -, , , , - .

    , , - , -, ...

  • 10 / - 2014

  • 11

    - - . - , , ,

    ;

    -

    , ,

    , -

    . -

    -

    - - - , - .

    - , 12%, 2013 . , -

    *

    *

    : :

  • 12 / - 2014

    , . , , , . , -, - - . , , . , , - . - -, , - , - , , - , - - -.

    , , , - , , ; , -

    -

    , . - , - -, , , - , 7/4/2012, , - - .

    , , , - . ; -

    , . . -, - . -, . - , ,

    12% 2013

    ,

  • 13

    ! - .

    , , , -; - ; -

    - , - , -. , , .

    2 . - 1.919 . - - 2014, - ;

    60%. - - . - , - . - , . , - - , -. , , - , . - . . , , - , . - . .

    , , , - , - -. , -, .

    - - - - - - , , -, . - - -

    , - - - , , - - . , -, , - - e- e-. - , - , - . -

  • 14 / - 2014

  • 15

    -, - - .

    . ; , -

    . - , - 50%, 20 10 , - rebate clawback. - , . - , 2011. , - 10% 1/1/2012 rebate clawback. . -, - . , , - .

    , - , - -, - . - ; - ; -

    -. -

    . - - . , , - - . - , - -. -, . , , - , ! - - .

    (- - ), ;

    , - , - , , - , - -, . , , -,

  • 16 / - 2014

    . - - . , -. .

    , , - - , . - ; -

    . - , - . , - - .

    , , - , - . . - -, ; , ,

    - , -

    , . , - , - - . , , - , - .

    - , - - - ;

    , , , - , . - , - , , - . -, - - - .

    ,

    2011

  • 17

    C

    M

    Y

    CM

    MY

    CY

    CMY

    K

    PHARMATHEN_21x28.pdf 1 26/4/2013 10:37:18 pi

  • 18 / - 2014

    : -. , , .

    - 2013 - - . :

    2012, 699.814 - 1.232.070 , - . , 1.930.000 ,

    ! 2013

    410 2013, 2012

  • 19

  • 20 / - 2014

    ! , , , .

    2013, 758.900 765.496 -, . , 1.520.000 , -. - . ,

    80.000.000 . , - . - ,

    , : , - , ..

    31-12-2013 387 , 127 - 260 -. - !

    - , -

    . - : - , 47.300 2013, - 41.300 2012, 12%.

    , -, - (25.488 ), - , 2013 24.700 16.800 2012.

    - - ( 2.000 ) , -, , , -, , , , -, , , .

    2.000 , -, 8 -! , - . 250.000 !

    31-12-2013 387

    : 127

    260

  • 21

  • 22 / - 2014

    /

    ..

    /

    %

    %

    1 1 ... 733 643 641 672 750 630 726 759 719 891 891 769 8.824 735,33 1,16% 4,82%

    2 ... 1325 2123 2091 2285 1792 1901 2048 1414 1968 1683 1195 1705 21.530 1.794,17 2,84% 11,77%

    3 .. 813 769 925 914 918 1098 970 1116 1105 1090 1134 826 11.678 973,17 1,54% 6,38%

    4 ... 567 567 545 547 500 536 560 511 518 517 612 514 6.494 541,17 0,86% 3,55%

    5 ... . 2373 1814 2250 2201 317 2494 2528 1161 246 2590 2462 240 20.676 1.723,00 2,72% 11,30%

    6 .. 1144 1189 1528 1686 1438 1385 874 976 1305 504 1248 852 14.129 1.177,42 1,86% 7,72%

    7 .. 935 766 831 799 770 688 722 601 941 563 813 808 9.237 769,75 1,22% 5,05%

    8 ... 443 349 407 489 472 367 413 271 427 489 453 447 5.027 418,92 0,66% 2,75%

    9 .. . 382 355 315 313 17 1.382 115,17 0,18% 0,76%

    10 ..... 1525 1438 1358 1626 1297 1366 1079 882 1426 1113 1410 1208 15.728 1.310,67 2,07% 8,60%

    11 ... 1050 1075 1034 1057 1078 1004 1052 1046 1102 1135 1138 86 11.857 988,08 1,56% 6,48%

    12 1849 1647 1526 1728 1545 1603 1563 1204 1559 1559 1531 1220 18.534 1.544,50 2,44% 10,13%

    13 .. 405 392 414 286 303 272 237 81 167 149 164 154 3.024 252,00 0,40% 1,65%

    14 . 168 340 273 307 98 150 135 51 160 214 168 321 2.385 198,75 0,31% 1,30%

    15 .. 5 6 118 126 111 0 366 30,50 0,05% 0,20%

    16 .. 275 254 230 273 200 225 202 158 130 256 251 2.454 204,50 0,32% 1,34%

    17 694 1120 842 989 921 1089 951 690 1051 1121 765 515 10.748 895,67 1,42% 5,88%

    18 850 832 846 885 827 851 785 748 867 890 854 800 10.035 836,25 1,32%

    19 756 714 689 735 722 727 758 570 785 805 834 730 8.825 735,42 1,16% 4,82%

    1 16.287 16.387 16.750 17.798 14.083 16.512 15.714 12.239 14.346 15.443 15.928 11.446 182.933 15.244,42 24,11% 100,00%

    2 1 251 276 292 271 249 273 219 128 248 296 271 180 2.954 246,17 0,39%

    2 .. 790 639 665 582 666 616 517 506 603 724 702 606 7.616 634,67 1,00%

    3 .. 1645 1599 1465 1588 1593 1724 1533 1426 1632 1667 1683 1549 19.104 1.592,00 2,52%

    4 .. 1126 1118 1172 1158 1182 1262 1162 1373 1184 1371 1424 1508 15.040 1.253,33 1,98%

    5 ... 898 806 907 868 836 759 655 847 847 940 841 966 10.170 847,50 1,34%

    6 271 671 585 799 741 752 504 502 689 772 911 653 7.850 654,17

    7 .... 2035 1829 1997 2363 2503 1833 2211 2017 1742 2003 2180 1983 24.696 2.058,00

    8 .. 243 215 340 241 291 256 260 225 255 220 187 199 2.932 244,33

    9 .. 257 234 215 259 262 261 356 296 296 285 381 446 3.548 295,67

    10 . . 385 321 348 329 245 354 358 387 372 432 362 421 4.314 359,50

    11 .. 117 80 63 71 87 117 152 139 132 144 223 154 1.479 123,25

    12 .. 312 381 10 379 97 212 10 472 100 449 422 355 3.199 266,58 0,42%

    13 .. 463 452 408 380 463 507 640 459 513 488 420 332 5.525 460,42

    2 8.793 8.621 8.467 9.288 9.215 8.926 8.577 8.777 8.613 9.791 10.007 9.352 108.427 9.035,58 14,29%

    3 1 .... 1575 1585 1441 1445 1122 1504 1248 1269 1370 1643 1452 1102 16.756 1.396,33 2,21%

    2 ... 3900 3772 3776 4152 3983 4010 3761 3324 4465 4355 4006 3806 47.310 3.942,50

    3 ../ 753 705 790 857 721 684 758 613 608 231 855 239 7.814 651,17

    4 .. 480 436 450 435 418 455 465 471 464 480 378 415 5.347 445,58

    5 .. 883 743 791 659 689 295 4.060 338,33

    6 .. 262 198 230 286 240 224 238 194 248 262 206 191 2.779 231,58

    7 .. 356 362 726 627 737 624 892 701 739 879 921 836 8.400 700,00

  • 23

    /

    ..

    /

    %

    %

    1 1 ... 733 643 641 672 750 630 726 759 719 891 891 769 8.824 735,33 1,16% 4,82%

    2 ... 1325 2123 2091 2285 1792 1901 2048 1414 1968 1683 1195 1705 21.530 1.794,17 2,84% 11,77%

    3 .. 813 769 925 914 918 1098 970 1116 1105 1090 1134 826 11.678 973,17 1,54% 6,38%

    4 ... 567 567 545 547 500 536 560 511 518 517 612 514 6.494 541,17 0,86% 3,55%

    5 ... . 2373 1814 2250 2201 317 2494 2528 1161 246 2590 2462 240 20.676 1.723,00 2,72% 11,30%

    6 .. 1144 1189 1528 1686 1438 1385 874 976 1305 504 1248 852 14.129 1.177,42 1,86% 7,72%

    7 .. 935 766 831 799 770 688 722 601 941 563 813 808 9.237 769,75 1,22% 5,05%

    8 ... 443 349 407 489 472 367 413 271 427 489 453 447 5.027 418,92 0,66% 2,75%

    9 .. . 382 355 315 313 17 1.382 115,17 0,18% 0,76%

    10 ..... 1525 1438 1358 1626 1297 1366 1079 882 1426 1113 1410 1208 15.728 1.310,67 2,07% 8,60%

    11 ... 1050 1075 1034 1057 1078 1004 1052 1046 1102 1135 1138 86 11.857 988,08 1,56% 6,48%

    12 1849 1647 1526 1728 1545 1603 1563 1204 1559 1559 1531 1220 18.534 1.544,50 2,44% 10,13%

    13 .. 405 392 414 286 303 272 237 81 167 149 164 154 3.024 252,00 0,40% 1,65%

    14 . 168 340 273 307 98 150 135 51 160 214 168 321 2.385 198,75 0,31% 1,30%

    15 .. 5 6 118 126 111 0 366 30,50 0,05% 0,20%

    16 .. 275 254 230 273 200 225 202 158 130 256 251 2.454 204,50 0,32% 1,34%

    17 694 1120 842 989 921 1089 951 690 1051 1121 765 515 10.748 895,67 1,42% 5,88%

    18 850 832 846 885 827 851 785 748 867 890 854 800 10.035 836,25 1,32%

    19 756 714 689 735 722 727 758 570 785 805 834 730 8.825 735,42 1,16% 4,82%

    1 16.287 16.387 16.750 17.798 14.083 16.512 15.714 12.239 14.346 15.443 15.928 11.446 182.933 15.244,42 24,11% 100,00%

    2 1 251 276 292 271 249 273 219 128 248 296 271 180 2.954 246,17 0,39%

    2 .. 790 639 665 582 666 616 517 506 603 724 702 606 7.616 634,67 1,00%

    3 .. 1645 1599 1465 1588 1593 1724 1533 1426 1632 1667 1683 1549 19.104 1.592,00 2,52%

    4 .. 1126 1118 1172 1158 1182 1262 1162 1373 1184 1371 1424 1508 15.040 1.253,33 1,98%

    5 ... 898 806 907 868 836 759 655 847 847 940 841 966 10.170 847,50 1,34%

    6 271 671 585 799 741 752 504 502 689 772 911 653 7.850 654,17

    7 .... 2035 1829 1997 2363 2503 1833 2211 2017 1742 2003 2180 1983 24.696 2.058,00

    8 .. 243 215 340 241 291 256 260 225 255 220 187 199 2.932 244,33

    9 .. 257 234 215 259 262 261 356 296 296 285 381 446 3.548 295,67

    10 . . 385 321 348 329 245 354 358 387 372 432 362 421 4.314 359,50

    11 .. 117 80 63 71 87 117 152 139 132 144 223 154 1.479 123,25

    12 .. 312 381 10 379 97 212 10 472 100 449 422 355 3.199 266,58 0,42%

    13 .. 463 452 408 380 463 507 640 459 513 488 420 332 5.525 460,42

    2 8.793 8.621 8.467 9.288 9.215 8.926 8.577 8.777 8.613 9.791 10.007 9.352 108.427 9.035,58 14,29%

    3 1 .... 1575 1585 1441 1445 1122 1504 1248 1269 1370 1643 1452 1102 16.756 1.396,33 2,21%

    2 ... 3900 3772 3776 4152 3983 4010 3761 3324 4465 4355 4006 3806 47.310 3.942,50

    3 ../ 753 705 790 857 721 684 758 613 608 231 855 239 7.814 651,17

    4 .. 480 436 450 435 418 455 465 471 464 480 378 415 5.347 445,58

    5 .. 883 743 791 659 689 295 4.060 338,33

    6 .. 262 198 230 286 240 224 238 194 248 262 206 191 2.779 231,58

    7 .. 356 362 726 627 737 624 892 701 739 879 921 836 8.400 700,00

  • 24 / - 2014

    /

    ..

    /

    %

    %

    8 .. 376 292 295 369 247 266 334 207 251 393 454 299 3.783 315,25

    9 .. 531 484 528 501 511 497 501 539 440 482 513 467 5.994 499,50

    10 .. 150 149 159 165 209 190 145 132 170 168 171 194 2.002 166,83

    11 .. 144 225 199 220 80 193 187 178 180 164 198 174 2.142 178,50

    3 9.410 8.951 9.385 9.716 8.957 8.942 8.529 7.628 8.935 9.057 9.154 7.723 106.387 8.865,58 14,02%

    4 1 ... 1451 1460 1502 1443 1527 1471 1450 1473 1548 1615 1366 1451 17.757 1.479,75 2,34%

    2 ... 1377 781 1090 1077 1104 1174 1160 1271 1370 1211 1283 1285 14.183 1.181,92 1,87%

    3 1091 1336 622 843 533 852 1046 785 950 1098 1168 945 11.269 939,08 1,48%

    4 .. 600 690 777 709 701 656 670 450 365 406 435 389 6.848 570,67

    5 ... 365 380 536 389 797 699 719 720 701 721 549 345 6.921 576,75

    6 .. 173 166 181 213 195 185 161 92 188 200 167 1.921 160,08

    7 .. 225 274 187 73 272 283 349 289 357 370 333 308 3.320 276,67

    8 .. 264 737 800 1037 822 873 968 826 904 962 904 948 10.045 837,08

    9 . 1218 1127 1090 1217 1204 1286 1236 1173 738 864 1333 978 13.464 1.122,00

    10 .. 661 585 561 638 690 595 627 555 639 144 23 5.718 476,50

    11 .. 1159 1095 1057 1114 785 1077 943 996 896 967 1056 860 12.005 1.000,42

    12 .. 310 534 584 632 421 565 587 645 332 156 4.766 397,17

    13 .. 284 280 161 271 331 210 202 171 261 280 287 257 2.995 249,58

    4 9.178 9.445 9.148 9.656 9.382 9.926 10.118 9.446 8.917 9.170 8.870 7.956 111.212 9.267,67 14,65%

    5 1 ... 1986 738 1704 1704 1756 1667 1804 1301 2059 1898 1185 2235 20.037 1.669,75

    2 .. 923 966 1009 1135 963 1070 988 414 371 979 1184 934 10.936 911,33

    3 .. 894 1203 1185 851 823 792 715 910 898 565 769 9.605 800,42

    4 .. 1035 1121 1117 1356 1259 1128 919 917 1123 1129 1324 1343 13.771 1.147,58

    5 .. 580 514 616 646 623 587 560 565 528 615 567 242 6.643 553,58

    6 .. 692 635 667 693 733 675 812 745 658 711 633 573 8.227 685,58

    7 .. 472 545 453 616 582 452 541 561 523 562 329 543 6.179 514,92

    8 .. 313 210 283 341 244 152 148 176 210 216 213 164 2.670 222,50

    9 .. 56 57 56 122 128 98 98 94 98 125 136 77 1.145 95,42

    10 .. 0 0,00

    5 6.951 4.786 7.108 7.798 7.139 6.652 6.662 5.488 6.480 7.133 6.136 6.880 79.213 6.601,08 10,44%

    6 1 ... 1795 1795 1811 2044 1761 1783 1993 1780 1851 1989 1735 1796 22.133 1.844,42 2,92%

    2 .. 722 726 734 956 907 835 874 853 885 910 798 733 9.933 827,75 1,31%

    3 ... 2476 2264 2182 2487 2075 1966 2677 2259 2571 2708 2653 2400 28.718 2.393,17

    4 .. 1105 1089 963 1178 1103 1325 1245 1238 1085 1155 1232 1256 13.974 1.164,50

    5 . 15 31 23 14 16 11 7 9 12 574 5 8 725 60,42

    6 .. 38 0 0 0 0 0 0 107 159 170 138 137 749 62,42

    7 . 868 770 532 440 726 802 867 763 714 632 642 7.756 646,33

    8 .. 138 222 144 141 134 129 126 114 129 150 150 134 1.711 142,58

    9 .. 454 421 482 426 473 432 328 386 472 507 646 5.027 418,92

    10 .. 293 287 322 334 281 303 329 294 302 301 270 283 3.599 299,92

    11 .. 161 203 171 105 185 202 235 193 189 236 262 181 2.323 193,58

    12 .. 560 520 543 525 587 572 646 589 590 743 654 545 7.074 589,50

    13 .. 207 273 215 622 310 309 224 384 250 178 227 3.199 266,58

  • 25

    /

    ..

    /

    %

    %

    8 .. 376 292 295 369 247 266 334 207 251 393 454 299 3.783 315,25

    9 .. 531 484 528 501 511 497 501 539 440 482 513 467 5.994 499,50

    10 .. 150 149 159 165 209 190 145 132 170 168 171 194 2.002 166,83

    11 .. 144 225 199 220 80 193 187 178 180 164 198 174 2.142 178,50

    3 9.410 8.951 9.385 9.716 8.957 8.942 8.529 7.628 8.935 9.057 9.154 7.723 106.387 8.865,58 14,02%

    4 1 ... 1451 1460 1502 1443 1527 1471 1450 1473 1548 1615 1366 1451 17.757 1.479,75 2,34%

    2 ... 1377 781 1090 1077 1104 1174 1160 1271 1370 1211 1283 1285 14.183 1.181,92 1,87%

    3 1091 1336 622 843 533 852 1046 785 950 1098 1168 945 11.269 939,08 1,48%

    4 .. 600 690 777 709 701 656 670 450 365 406 435 389 6.848 570,67

    5 ... 365 380 536 389 797 699 719 720 701 721 549 345 6.921 576,75

    6 .. 173 166 181 213 195 185 161 92 188 200 167 1.921 160,08

    7 .. 225 274 187 73 272 283 349 289 357 370 333 308 3.320 276,67

    8 .. 264 737 800 1037 822 873 968 826 904 962 904 948 10.045 837,08

    9 . 1218 1127 1090 1217 1204 1286 1236 1173 738 864 1333 978 13.464 1.122,00

    10 .. 661 585 561 638 690 595 627 555 639 144 23 5.718 476,50

    11 .. 1159 1095 1057 1114 785 1077 943 996 896 967 1056 860 12.005 1.000,42

    12 .. 310 534 584 632 421 565 587 645 332 156 4.766 397,17

    13 .. 284 280 161 271 331 210 202 171 261 280 287 257 2.995 249,58

    4 9.178 9.445 9.148 9.656 9.382 9.926 10.118 9.446 8.917 9.170 8.870 7.956 111.212 9.267,67 14,65%

    5 1 ... 1986 738 1704 1704 1756 1667 1804 1301 2059 1898 1185 2235 20.037 1.669,75

    2 .. 923 966 1009 1135 963 1070 988 414 371 979 1184 934 10.936 911,33

    3 .. 894 1203 1185 851 823 792 715 910 898 565 769 9.605 800,42

    4 .. 1035 1121 1117 1356 1259 1128 919 917 1123 1129 1324 1343 13.771 1.147,58

    5 .. 580 514 616 646 623 587 560 565 528 615 567 242 6.643 553,58

    6 .. 692 635 667 693 733 675 812 745 658 711 633 573 8.227 685,58

    7 .. 472 545 453 616 582 452 541 561 523 562 329 543 6.179 514,92

    8 .. 313 210 283 341 244 152 148 176 210 216 213 164 2.670 222,50

    9 .. 56 57 56 122 128 98 98 94 98 125 136 77 1.145 95,42

    10 .. 0 0,00

    5 6.951 4.786 7.108 7.798 7.139 6.652 6.662 5.488 6.480 7.133 6.136 6.880 79.213 6.601,08 10,44%

    6 1 ... 1795 1795 1811 2044 1761 1783 1993 1780 1851 1989 1735 1796 22.133 1.844,42 2,92%

    2 .. 722 726 734 956 907 835 874 853 885 910 798 733 9.933 827,75 1,31%

    3 ... 2476 2264 2182 2487 2075 1966 2677 2259 2571 2708 2653 2400 28.718 2.393,17

    4 .. 1105 1089 963 1178 1103 1325 1245 1238 1085 1155 1232 1256 13.974 1.164,50

    5 . 15 31 23 14 16 11 7 9 12 574 5 8 725 60,42

    6 .. 38 0 0 0 0 0 0 107 159 170 138 137 749 62,42

    7 . 868 770 532 440 726 802 867 763 714 632 642 7.756 646,33

    8 .. 138 222 144 141 134 129 126 114 129 150 150 134 1.711 142,58

    9 .. 454 421 482 426 473 432 328 386 472 507 646 5.027 418,92

    10 .. 293 287 322 334 281 303 329 294 302 301 270 283 3.599 299,92

    11 .. 161 203 171 105 185 202 235 193 189 236 262 181 2.323 193,58

    12 .. 560 520 543 525 587 572 646 589 590 743 654 545 7.074 589,50

    13 .. 207 273 215 622 310 309 224 384 250 178 227 3.199 266,58

  • 26 / - 2014

    /

    ..

    /

    %

    %

    14 .. 466 468 536 558 556 483 541 590 505 499 591 563 6.356 529,67

    15 .. 446 529 591 409 523 489 636 475 627 578 579 583 6.465 538,75

    16 . 416 448 450 521 472 288 476 462 81 5 412 355 4.386 365,50

    17 . 184 154 110 145 33 110 190 202 44 217 1.389 115,75

    18 .. 294 245 267 289 254 357 260 364 246 349 317 265 3.507 292,25 0,46%

    19 .. 85 128 93 106 181 196 212 173 132 1.306 108,83

    6 10.638 10.445 9.966 10.182 10.662 10.337 11.700 10.985 11.237 12.252 11.469 10.457 130.330 10.860,83 17,17%

    7 1 ... - 1321 1280 996 946 1339 1133 1302 1210 1310 1390 1018 1246 14.491 1.207,58 1,91%

    2 .. 1059 1026 1010 1395 856 1451 1142 943 1036 1122 978 975 12.993 1.082,75

    3 .. 394 369 356 575 671 214 515 384 549 617 640 378 5.662 471,83

    4 .. 471 406 479 535 386 498 497 444 525 378 126 4.745 395,42

    5 .. 140 160 189 199 189 212 221 208 161 136 122 1.937 161,42

    6 ..-.. 33 38 23 29 36 36 60 40 52 67 90 65 569 47,42

    7 3.418 3.279 2.574 3.623 3.437 3.409 3.729 3.295 3.599 3.882 3.240 2.912 40.397 3.366,42 5,32%

    . 1* 64.675 61.914 63.398 68.061 62.875 64.704 65.029 57.858 62.127 66.728 64.804 56.726 758.899 63.241,58 146,26%

    . 2* 1 251 . . 6.700

    2 401 . . 10.000

    3 4.500

    4 424 . / 3.000

    . 3* /

    765.496

    1.548.595

    1*: .

    2*:

    3*:

    2011 10.813.386

    1000 143,21

    90 8.432,21

    MO

    68.061

    66.728

    65.029

    64.804

    64.704

    64.675

    63.398

    62.875

    62.127

    61.914

    57.858

    56.726

    758.899 63.242

  • 27

    /

    ..

    /

    %

    %

    14 .. 466 468 536 558 556 483 541 590 505 499 591 563 6.356 529,67

    15 .. 446 529 591 409 523 489 636 475 627 578 579 583 6.465 538,75

    16 . 416 448 450 521 472 288 476 462 81 5 412 355 4.386 365,50

    17 . 184 154 110 145 33 110 190 202 44 217 1.389 115,75

    18 .. 294 245 267 289 254 357 260 364 246 349 317 265 3.507 292,25 0,46%

    19 .. 85 128 93 106 181 196 212 173 132 1.306 108,83

    6 10.638 10.445 9.966 10.182 10.662 10.337 11.700 10.985 11.237 12.252 11.469 10.457 130.330 10.860,83 17,17%

    7 1 ... - 1321 1280 996 946 1339 1133 1302 1210 1310 1390 1018 1246 14.491 1.207,58 1,91%

    2 .. 1059 1026 1010 1395 856 1451 1142 943 1036 1122 978 975 12.993 1.082,75

    3 .. 394 369 356 575 671 214 515 384 549 617 640 378 5.662 471,83

    4 .. 471 406 479 535 386 498 497 444 525 378 126 4.745 395,42

    5 .. 140 160 189 199 189 212 221 208 161 136 122 1.937 161,42

    6 ..-.. 33 38 23 29 36 36 60 40 52 67 90 65 569 47,42

    7 3.418 3.279 2.574 3.623 3.437 3.409 3.729 3.295 3.599 3.882 3.240 2.912 40.397 3.366,42 5,32%

    . 1* 64.675 61.914 63.398 68.061 62.875 64.704 65.029 57.858 62.127 66.728 64.804 56.726 758.899 63.241,58 146,26%

    . 2* 1 251 . . 6.700

    2 401 . . 10.000

    3 4.500

    4 424 . / 3.000

    . 3* /

    765.496

    1.548.595

    / 2013:

    /

    2 2 1 GENERAL1 1 ALLURA X-per FD 10 PHILIPS1 MD HOSPITAL ARTIS DFC SIEMENS1 1 1 1 1 1 INTEGRIS HM 2000 PHILIPS1 METROPOLITAN INTEGRIS H 3000 PHILIPS1 MEDITERRANEO ALLURA X-per FD 10 PHILIPS4 AXIOM ARTIS DSC ARTIS FA ARTIS ZEE COROSKOP SIEMENS4 AXIOM ARTIS DSC ARTIS FA ANGIOSTAR COROSKOP SIEMENS1 EUROMEDICA - 2 EUROMEDICA - INNOVA 3100 IQ GE Healthcare1 1 PHILIPS1 AXIOM ARTIS FC SIEMENS1 CRETA INTERCLINIC INNOVA 3100 GE Healthcare1 ARTIS FC SIEMENS32 21

  • 28 / - 2014

    / 1* 2* 3* 4* 5* 6* 7*

    A B A B A B A B A B A B A B A B A B A B A B A B

    1

    252 104 231 100 225 91 324 138 226 89 251 100 284 117 175 76 242 116 264 116 307 128 271 114 3.052 254 1.289 9,30 42,23 8,99 3 INTEGRIS ALLURA 9/9 INTEGRIS ALLURA FD COROSCOP HiP

    PHILIPS PHILIPS SIEMENS

    2 ... 140 49 123 34 161 63 153 46 121 39 101 32 84 35 110 37 114 32 140 35 119 44 1.366 114 446 3,22 32,65 4,02 2 COROSCOP TOP INNOVA 2000

    SIEMENS GE Healthcare

    3 ... 352 82 351 81 338 78 394 108 328 77 299 66 332 68 169 60 285 90 332 84 367 103 268 71 3.815 318 968 6,98 25,37 11,24 2 ALLURA Xper FD 10 COROSCOP TOP

    PHILIPS SIEMENS

    4 .... 64 22 76 40 76 53 53 5 78 27 70 30 470 39 124 0,89 26,38 1,38 2 INNOVA 2000 INNOVA 2000

    GE Healthcare

    5 ... 178 77 146 67 69 34 162 77 555 46 255 1,84 45,95 1,64 1 COROSCOP TOP SIEMENS

    6 ... . 103 38 78 50 75 38 81 57 71 32 61 35 77 27 39 18 68 33 77 37 106 44 83 46 919 77 455 3,28 49,51 2,71 2 ALLURA Xper FD 10 ALLURA XperFD 10

    PHILIPS

    7 ... 64 15 54 15 57 12 55 11 58 16 47 20 51 15 45 12 42 8 50 14 60 19 56 17 639 53 174 1,25 27,23 1,88 1 ALLURA Xper FD 10 PHILIPS

    8 ... 93 42 70 27 58 33 74 32 86 41 83 39 96 48 24 15 41 25 122 43 94 43 78 39 919 77 427 3,08 46,46 2,71 1 INTEGRIS CV9 PHILIPS

    9 .. 120 52 106 41 116 37 142 43 101 31 112 34 121 32 38 14 134 43 112 36 120 28 100 36 1.322 110 427 3,08 32,30 3,90 1 ALLURA Xper FD 20 PHILIPS

    10 .. 39 15 35 9 37 23 39 21 40 19 49 18 37 14 12 5 53 26 44 0 46 12 47 18 478 40 180 1,30 37,66 1,41 1 ARTIS TA SIEMENS

    11 .. 123 48 110 42 125 41 148 69 124 61 119 47 113 46 98 47 116 43 120 59 128 55 117 65 1.441 120 623 4,49 4,25 2 AXIOM ARTIS COROSKOP TOP

    SIEMENS

    12 1.400 117 800 5,77 57,14 4,13 2 INTEGRIS H3000 ALLURA Xper FD 10

    PHILIPS

    13 .. 21 3 16 8 1 ALLURA Xper FD 10 PHILIPS

    14 .. 56 22 51 11 39 14 44 16 79 42 33 0 37 40 24 31 92 39 89 45 93 51 83 33 720 60 344 2,48 47,78 2,12 1 COROSKOP TOP SIEMENS

    15 .. 108 41 91 30 85 23 83 29 88 29 78 35 89 26 50 16 86 25 126 43 105 32 81 36 1.070 89 365 2,63 34,11 3,15 1 COROSCOP TOP SIEMENS

    16 .. 59 23 46 16 44 9 53 19 53 26 49 24 57 20 33 15 56 14 47 26 51 30 51 26 599 50 248 1,79 41,40 1,76 1 AXIOM ARTIS ZEE SIEMENS

    17 .. 1 AXIOM ARTIS ZEE SIEMENS

    18 ... 165 74 143 70 133 61 154 67 126 62 127 69 142 60 96 53 139 73 142 71 139 63 128 54 1.634 136 777 5,60 47,55 4,81 1 AXIOM ARTIS DFC SIEMENS

    19 ... 167 64 169 53 123 55 185 63 152 62 138 46 141 59 125 54 108 42 97 37 99 40 60 14 1.564 FALSE 589 4,25 37,66 4,61 1 ALLURA Xper FD 10 PHILIPS

    20 .... 198 91 200 79 206 85 213 98 85 38 176 78 217 78 133 57 206 63 220 67 174 69 212 73 2.240 187 876 6,32 39,11 6,60 1 INNOVA 2000 GE Healthcare

    21 .. 4 0 4 0 0 0,00 0,00 #REF! 1 ARTIS ZEE SIEMENS

    22 ... 88 46 79 53 57 27 104 77 69 40 73 58 66 52 54 42 70 45 88 55 117 72 80 55 945 79 622 4,49 65,82 2,78 1 ADVANTIX LCA GE Healthcare

    23 ... 120 24 109 22 115 38 147 44 103 39 124 34 128 29 93 38 130 31 128 52 126 42 149 16 1.472 123 409 2,95 27,79 4,34 2 INEGRIS H3000 PHILIPS

    24 ... 203 75 186 24 147 75 212 78 170 107 167 93 186 118 162 93 190 107 181 96 188 94 108 94 2.100 175 1.054 7,60 50,19 6,19 1 INTEGRIS ALLURA FD 10 PHILIPS

    25 ... 177 72 167 54 154 38 162 51 160 62 165 53 140 52 130 53 146 66 146 66 188 94 126 55 1.861 155 716 5,16 38,47 5,48 2 INTEGRIS ALLURA 9C INTEGRIS ALLURA 15

    PHILIPS

    26 .. 60 27 53 19 40 20 52 18 42 16 43 14 52 17 46 16 38 11 67 23 55 22 52 26 600 50 229 1,65 38,17 1,77 1 ARTIS ZEE SIEMENS

    27 .. 13 1 12 2 11 2 14 0 0 0 12 1 19 6 0 0 7 0 13 2 7 2 4 0 112 9 16 0,12 14,29 0,33 1 OEC 9900 GE Healthcare

    28 ... -

    189 105 215 165 208 254 170 162 102 198 100 192 123 168 96 184 138 232 163 236 138 248 130 2.486 207 1.430 10,31 57,52 7,32 2 ALLURA X-per FD-10 ARTIS ZEE

    PHILIPS SIEMENS

    29 .. 13 2 14 1 17 2 15 2 12 0 17 4 13 1 11 0 11 1 10 4 10 3 13 4 156 13 24 0,17 15,38 0,46 1 BV VERADIOUS PHILIPS

    2902 1112 2693 998 2571 865 3102 1257 2335 991 2784 1106 2913 1187 1954 880 2769 1153 2874 1.176 3055 1249 2624 1104 33.939 2.828 13.867 100,00 40,86 100,00 40

    1*: 2*: .. / 3*: 4*: % PCI 5*: % PCI 6*: % 7*:

    A: B:

  • 29

    / 1* 2* 3* 4* 5* 6* 7*

    A B A B A B A B A B A B A B A B A B A B A B A B

    1

    252 104 231 100 225 91 324 138 226 89 251 100 284 117 175 76 242 116 264 116 307 128 271 114 3.052 254 1.289 9,30 42,23 8,99 3 INTEGRIS ALLURA 9/9 INTEGRIS ALLURA FD COROSCOP HiP

    PHILIPS PHILIPS SIEMENS

    2 ... 140 49 123 34 161 63 153 46 121 39 101 32 84 35 110 37 114 32 140 35 119 44 1.366 114 446 3,22 32,65 4,02 2 COROSCOP TOP INNOVA 2000

    SIEMENS GE Healthcare

    3 ... 352 82 351 81 338 78 394 108 328 77 299 66 332 68 169 60 285 90 332 84 367 103 268 71 3.815 318 968 6,98 25,37 11,24 2 ALLURA Xper FD 10 COROSCOP TOP

    PHILIPS SIEMENS

    4 .... 64 22 76 40 76 53 53 5 78 27 70 30 470 39 124 0,89 26,38 1,38 2 INNOVA 2000 INNOVA 2000

    GE Healthcare

    5 ... 178 77 146 67 69 34 162 77 555 46 255 1,84 45,95 1,64 1 COROSCOP TOP SIEMENS

    6 ... . 103 38 78 50 75 38 81 57 71 32 61 35 77 27 39 18 68 33 77 37 106 44 83 46 919 77 455 3,28 49,51 2,71 2 ALLURA Xper FD 10 ALLURA XperFD 10

    PHILIPS

    7 ... 64 15 54 15 57 12 55 11 58 16 47 20 51 15 45 12 42 8 50 14 60 19 56 17 639 53 174 1,25 27,23 1,88 1 ALLURA Xper FD 10 PHILIPS

    8 ... 93 42 70 27 58 33 74 32 86 41 83 39 96 48 24 15 41 25 122 43 94 43 78 39 919 77 427 3,08 46,46 2,71 1 INTEGRIS CV9 PHILIPS

    9 .. 120 52 106 41 116 37 142 43 101 31 112 34 121 32 38 14 134 43 112 36 120 28 100 36 1.322 110 427 3,08 32,30 3,90 1 ALLURA Xper FD 20 PHILIPS

    10 .. 39 15 35 9 37 23 39 21 40 19 49 18 37 14 12 5 53 26 44 0 46 12 47 18 478 40 180 1,30 37,66 1,41 1 ARTIS TA SIEMENS

    11 .. 123 48 110 42 125 41 148 69 124 61 119 47 113 46 98 47 116 43 120 59 128 55 117 65 1.441 120 623 4,49 4,25 2 AXIOM ARTIS COROSKOP TOP

    SIEMENS

    12 1.400 117 800 5,77 57,14 4,13 2 INTEGRIS H3000 ALLURA Xper FD 10

    PHILIPS

    13 .. 21 3 16 8 1 ALLURA Xper FD 10 PHILIPS

    14 .. 56 22 51 11 39 14 44 16 79 42 33 0 37 40 24 31 92 39 89 45 93 51 83 33 720 60 344 2,48 47,78 2,12 1 COROSKOP TOP SIEMENS

    15 .. 108 41 91 30 85 23 83 29 88 29 78 35 89 26 50 16 86 25 126 43 105 32 81 36 1.070 89 365 2,63 34,11 3,15 1 COROSCOP TOP SIEMENS

    16 .. 59 23 46 16 44 9 53 19 53 26 49 24 57 20 33 15 56 14 47 26 51 30 51 26 599 50 248 1,79 41,40 1,76 1 AXIOM ARTIS ZEE SIEMENS

    17 .. 1 AXIOM ARTIS ZEE SIEMENS

    18 ... 165 74 143 70 133 61 154 67 126 62 127 69 142 60 96 53 139 73 142 71 139 63 128 54 1.634 136 777 5,60 47,55 4,81 1 AXIOM ARTIS DFC SIEMENS

    19 ... 167 64 169 53 123 55 185 63 152 62 138 46 141 59 125 54 108 42 97 37 99 40 60 14 1.564 FALSE 589 4,25 37,66 4,61 1 ALLURA Xper FD 10 PHILIPS

    20 .... 198 91 200 79 206 85 213 98 85 38 176 78 217 78 133 57 206 63 220 67 174 69 212 73 2.240 187 876 6,32 39,11 6,60 1 INNOVA 2000 GE Healthcare

    21 .. 4 0 4 0 0 0,00 0,00 #REF! 1 ARTIS ZEE SIEMENS

    22 ... 88 46 79 53 57 27 104 77 69 40 73 58 66 52 54 42 70 45 88 55 117 72 80 55 945 79 622 4,49 65,82 2,78 1 ADVANTIX LCA GE Healthcare

    23 ... 120 24 109 22 115 38 147 44 103 39 124 34 128 29 93 38 130 31 128 52 126 42 149 16 1.472 123 409 2,95 27,79 4,34 2 INEGRIS H3000 PHILIPS

    24 ... 203 75 186 24 147 75 212 78 170 107 167 93 186 118 162 93 190 107 181 96 188 94 108 94 2.100 175 1.054 7,60 50,19 6,19 1 INTEGRIS ALLURA FD 10 PHILIPS

    25 ... 177 72 167 54 154 38 162 51 160 62 165 53 140 52 130 53 146 66 146 66 188 94 126 55 1.861 155 716 5,16 38,47 5,48 2 INTEGRIS ALLURA 9C INTEGRIS ALLURA 15

    PHILIPS

    26 .. 60 27 53 19 40 20 52 18 42 16 43 14 52 17 46 16 38 11 67 23 55 22 52 26 600 50 229 1,65 38,17 1,77 1 ARTIS ZEE SIEMENS

    27 .. 13 1 12 2 11 2 14 0 0 0 12 1 19 6 0 0 7 0 13 2 7 2 4 0 112 9 16 0,12 14,29 0,33 1 OEC 9900 GE Healthcare

    28 ... -

    189 105 215 165 208 254 170 162 102 198 100 192 123 168 96 184 138 232 163 236 138 248 130 2.486 207 1.430 10,31 57,52 7,32 2 ALLURA X-per FD-10 ARTIS ZEE

    PHILIPS SIEMENS

    29 .. 13 2 14 1 17 2 15 2 12 0 17 4 13 1 11 0 11 1 10 4 10 3 13 4 156 13 24 0,17 15,38 0,46 1 BV VERADIOUS PHILIPS

    2902 1112 2693 998 2571 865 3102 1257 2335 991 2784 1106 2913 1187 1954 880 2769 1153 2874 1.176 3055 1249 2624 1104 33.939 2.828 13.867 100,00 40,86 100,00 40

  • 30 / - 2014

    10 - 2014 Fiercepharma,

    - .

    - Fiercepharma, , - 34 . . - .

    - 2014 - 6 . ., . , (2014-

    2013) - , 2012, 55 . . , 2015, - - 66 . .

    , - Teva Pharmaceutucal Industries, Copaxone. - . Teva , -, .

    Fiercepharma, Copaxone

    Fiercepharma

    Top 10 2014

    34 . .

    6 , ,

  • 31

  • 32 / - 2014

    2014, 2015, , - 3 . ., , .

    AstraZeneca, - , Nexium. 2014. - 4 . . 2012, 2,3 . - .

    , - 2014.

    Novartis - Sandostatin LAR Exforge, top 10 Fiercepharma. - Allergan, Restasis Lumigan, - top 10. Lumigan , - 2017.

    Fiercepharma - 2012. Boehringen Ingelheim Allergan , . , - - . - - ( Boehringer Sanofi), - .

    1. Copaxone, Teva

    Copaxone ( ): : Teva Pharmaceutical Industries 2012: 3.996.000.000 . 2012: 2.900.000.000 . : 2014

    - - . Teva , - Copaxone.

    Teva Pharmaceutical Industries - 2010 2011, - Cephalon, Nuvigil Provigil - Treanda.

    , Copaxone (66%) - (20%) . , , Fiercepharma, Copaxone - Teva Pharmaceutical Industries, - 12%.

    (2013) Copaxone - , - Novartis (

    2015

    66 .

    .

    Teva Pharmaceutical Industries,

    1

  • 33

    Gilenya), Tecfidera, Biogen Idec.

    17% - 2013, Copaxone 9% -, Tecfidera. , . , Teva Pharmaceutical Industries, 2014.

    , Teva Copaxone, - . , - Mylan, , - Copaxone, -.

    2. Nexium, AstraZeneca

    Nexium (esomeprazole magnesium): , () 2012: 3.994.000.000 . 2012: 2.272.000.000 . : 2014

    - - Seroquel, AstraZeneca - , Nexium. , -

    , 31% 2013, - 438 . .

    2016, AstraZeneca - , , Crestor. - top seller 2012, - 6,2 . ., , Lipitor.

    , - , Nexium. 4 . . - 2012.

    2012, AstraZeneca - -, Bristol-Myers Squibb, 7 . . Amylin Pharmaceuticals, - , Byetta Bydureon. , . - 1 . ., Onglyza , - .

    3. Micardis/Micardis HCT, Boehringer Ingelheim

    Micardis/Micardis HCT () : Boehringer Ingelheim

    AstraZeneca,

    2 3

  • 34 / - 2014

    2012: 2.217.000.000 . 2012: ( ) : 2014

    Boehringer Ingelheim - blockbuster - .

    Micardis Boehringer Ingelheim - 2011.

    - , Micardis, Aggrenox -

    , Atrovent Combivent ().

    , 2011 32% 2012. , , - 2013, Micardis .

    4. Sandostatin LAR, Novartis

    Sandostatin LAR ( ): 2012: 1.512.000.000 . 2012:

    649.000.000 . : 2014

    Sandostatin LAR ( -, - ), - .

    Sandostatin LAR -, , , -. Sandostatin LAR , 2010.

    , - .

    5. Exforge/Exforge HCT, Novartis

    Exforge/Exforge HCT (/): 2012: 1.352.000.000 . 2012: 358.000.000 . : 2014

    Exforge Novartis 2007 , - (-), - () .

    , Novartis

    Top 10 Novartis

    4 5

  • 35

    . 2010, - 422 . . , - , - Exforge, - Diovan Rasilez. , , DDMAC, - .

    Exforge 1,4 . ., , - , - 358 . . - 2012.

    6. Nasonex, MerckNasonex ( -): 2012: 1.268.000.000 . 2012: 597.000.000 . : 2014 ( )

    Merck - Nasonex Schering-Plough 2009. - Apotex, , - - -. ,

    , 1,3 . . , 2012. , 2013 711 -. . .

    2012, Nasonex , 2014, 2017 Apotex - . Merck, , , Apotex . , 2013, - Apotex Merck.

    Merck 2017, Nasonex - - . - Nasonex 2014, Apotex - FDA .

    7. Trilipix, AbbVie

    Trilipix ( ): / 2012: 1.098.000.000 . 2012: 1.098.000.000 . : 2014

    2014

    6 7

  • 36 / - 2014

    ( - 2013)

    Abbott Laboratories, 2013, AbbVie .

    Trilipix, Humira, 9,3 . . 2012. Humira -, AbbVie - .

    AbbVie Trilipix, - TriCor 2014, , , . Trilipix TriCor (- - ), 1 . . 2012.

    , , Trilipix. Abbott Par Pharmaceutical Mylan - 2014, , , . - 2013.

    Par Pharmaceutical Mylan - -, - HDL.

    , AbbVie 2013 -

    Trilipix TriCor - . , - 2013 58%, - 235 . .

    8. Evista, Eli Lilly

    Evista ( HCI): , - 2012: 1.010.000.000 . 2012: 699.000.000 . : 2014

    Evista Eli Lilly , - .

    2013, , ( taxomifen) - .

    40 70 - . 11 Evista, Evista.

    Fiercepharma

    2012

    Boehringer Ingelheim Allergan

    8

  • 37

    9. Renagel/Renvela, Sanofi

    Renagel/Renvela ( - ): 2012: 861.000.000 . 2012: 595.000.000 . : 2014

    Renagel Renvela - blockbusters Sanofi. - - .

    - 861 . . 2012 538 . . 2011. 2013, - 346 . . 450 . .

    , Sanofi - - - Renvela 2014. Renvela Renagel .

    10. Restasis, Allergan

    Restasis ( ): 2012: 792.000.000 . 2012: : 2014

    - Restasis Allergan, - 2013.

    FDA - - , Allergan, - 12%. , CEO Allergan, David Pyott, FDA, - .

    , FDA -. Allergan .

    Allergan

    /

    1 Copaxone Teva

    2 Nexium AstraZeneca

    3 Micardis/Micardis HCT Boehringer Ingelheim

    4 Sandostatin LAR Novartis

    5 Exforge/Exforge HCT Novartis

    6 Nasonex Merck

    7 Trilipix AbbVie

    8 Evista Eli Lilly

    9 Renagel/Renvela Sanofi

    10 Restasis Allergan

    : Fiercepharma

    9 10

  • 38 / - 2014

    (..), - , - . - -

    , 514 , 66 , 58 . , 2,4 - , , - , -. , - 506 . .

    ""

    "" ..

    - 2016

  • 39

  • 40 / - 2014

    , ,

    - - , . - - - - ( - ), - , - .. 2016.

    , , -

    , , ! - - 65% -! , , . -, , .

    - - , . , . , - 20 mg ml , , - - .

    - , .

    - , menthol, - , - 2020.

    - - 3% .. -, .

  • 41

    "slim" &

    slim , - , -. , - 20 - -, . , - , , - 30 - , - .

    lobbying , - Linda McAvan, - - . , , . , - 18 .

    - - -

    , , -, - - .

    , - Research - , PhB - - - - . , 92,5%.

    -, , , , -, - - .

    Research, - , 70,7% , - .

    , - .

    "slim"

  • 42 / - 2014

    -, .

    -, 7 - , - .

    , - . 24 1142 - , - , - - .

    , , - - , , -, , . -, , - .

    ""

    28% 500 - , -. , 700

    5,4 - - 6 - .

    , - 25 . . , - , - -. , - 8 . - 600 - .

    (), 100 20 , , 21 .

    , , - (IHME), 2012 34,7%. , , - 19 , Research - 14,8% (14,4% , 15,4% -) 10,6% (10,4% , 11% ). , - 2000 - 2009, , - .

    lobbying

    L. McAvan

  • 43

  • 44 / - 2014

    (guidelines) (AHA) (ACC),1 , , , -, , , -

    40-75 !

    ; . , , - - . , - -

    . - - , - .2 , , . , , , , , -

    !

    ""

    ,

    ,

    guidelines, 40-75 !

  • 45

  • 46 / - 2014

    , -!3 , - (guidelines) . , - - : guidelines;

    ,

    -, -, ,

    30 , - . , - -, - , -, . - - - , , - , - .4, 5 , -, , - -

    , - - , - , .

    guidelines , , - , - . , , - , JAMA, - , , -

    , - . , . , guidelines, , - .6

    - - - . - ,

    ,

    ,

  • 47

    , - , . -. , - , - . - -, , -, , , ,

    stress. , - , , - - , - -, , , , -. , - - , .

    , ,

    -, - - . guidelines , . 10 10-20% - , - guidelines ( NICE 20%), 7.5% 5%! ; - 40 , , -

    70%! - , , , , - ; : 140 , - -, ! , - 18 -, , - , , , , . New York Times Rita Redberg ( JAMA) Dr John Abramson (lecturer at Harvard

    -

  • 48 / - 2014

    Medical School), - BMJ.7, 8

    , , - - calculator! - , . calculator, - , 7.5% . , , , -, -. guidelines calculator -, 75-150%, 50 7.5 ! -, , score 4, -, score 8! Lancet, New York Times, Paul Ridken Nancy Cook, guidelines . , calculator .9, 10 - calculator , leading cardiologist

    ACC, Steven Nissen, . -: Something is terrible wrong!.11

    " "

    (turmoil ), - AHA, - , guidelines. - - , guidelines calculator. - - - -, - ( ). calculator, , , 50 !

    - , - , , . calculator . ; -, 50 . ! guidelines . ,

    guidelines

  • 49

    . , , - , - . , , -! ; -

    - , - , - ; , guidelines , FDA! - , , - , - !12 , - guidelines - - , . Corruption in a legal way - . , , guidelines , .

    , , guidelines, - , -

    . , , - wrecking ball - guidelines.13 guidelines -, - , -, .14

    -, , guidelines, - moneylines, !

    , 50 - - . - , - - , , -, , , ..2 - . , - , . , , , - -. -. ! -

    guidelines

    ,

  • 50 / - 2014

    , guidelines , . , - . , - .

    !

    - -

    - - . - .3

    118.160 50 - - , LDL () -, - 190 mg/ml LDL 115 mg/ml, ! , () LDL - !

    , - .

    , - , , . -, - (1 500 ), 320 mg/ml, -, guidelines . , LDL - () HDL. , - LDL HDL, -

    , - , .

    ;

    ! , - , -. 20% 7.5%, 0% ; 190 mg/dl - -. ! - -

    calculator!

  • 51

    (hired) , , - , - -. opinion leader 310 mg 0% 1% 2% ; - guidelines! , ; - -, - ; -

    - , - ; guidelines. , , - ! , , , , , - , - - .

    1. Stone N, Robinson J, Lichtenstein A, et al. 2013

    ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, published online November 12, 3013

    2. An apple (or statin) a day will keep the doctor away: Population Health Analysis. Medscape. Dec 18, 2013

    3. Bathoum L, Depont Christensen R, Engers Pedersen L, et al. Association of lipoprotein level with mortality in subjects aged 50+ without previous diabetes or cardiovascular disease: A population-based register study. Scand J Prim Health Care, 2013 Sept;31(3):172-80

    4. Sultan S, Hynes N. The Ugly Side of Statins. Systemic Appraisal of the Contemporary Un-Known Unknowns. OJEMD, 2013, 3, 179-185

    5. Malhotra A. Saturated fat is not the major issue. BMJ 2013, 347:f6340

    6. John P. A. Ioannidis. More than a billion people taking statins? Potential implications of the new cardiovascular guidelines. JAMA, published online December 02, 2013

    7. Abramson JD, Redberg RF. Dont Give More Patients Statins. The New York Times. November 13, 2013

    8. Abramson JD, Rosenberg HG, Jewell N, et al. Should people at low risk of cardiovascular disease take a statin? BMJ 2013;347:f6123

    9. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. The Lancet, early on line publication, 20 November 2

    10. Risk Calculator for Cholesterol Appears Flawed. The New York Times. November 17, 2013

    11. How good is the new ACC/AHA risk calculator? Medscape. November 18, 2013

    12. U.S. FDA says new cholesterol drugs may not need outcome studies.www.reuters.com Nov 14, 2013

    13. Cardiology in 2013: Like a wrecking ball. The guidelines wrecking ball. Cardiobrief. Dec 26, 2013

    14. Endocrinology Group Rejects New AHA/ACC CVD Guidelines www.medscape.com Dec 13, 2013

    , ,

    guidelines,

    moneylines, !

  • 52 / - 2014

    . , , , - . , -

    .

    - 25%, - 27%, 24 54%! , , , -. - 40%

    . 30% . -, , , - - . , - .

    ""

    . *

    * . : - -, , , 1 - . : , , -, - .

    , ,

  • 53

  • 54 / - 2014

    - : - - .

    -, , , , - - - ,

    .

    - - , , - . - -, , - , - . 2008.

    - -

    - - . , - .(1) .(2, 3).

    - -. - . -

    70%. - 2,8 100.000 2008 5,2 2010.(4) - - - , - .(5) , 1 6 18-70 - 12 (600.000) . - 75% - - .

    - , - , : , -

  • 55

    , - . - , .(6)

    - - . - - - , .(7)

    - , - , , , , -, .

    - -. , , , . , -, .

    - -. -

    , , , - , . - . - , , , , - , - , , -

    , , - .

    - - - - , .

    - , . - , , - , -

    70%

  • 56 / - 2014

    .

    - shock, - - - , , , , - -, .

    , - -, - (, -). , , - - , - .

    - - . - - . , - . , , -

    -, , - , . - - , - . - , , .

    , , , - , - , -, , , - . , - ( -) . - , .

    - - .

    H - . - .

    2,8

    100.000 2008,

    5,2 2010

    , ,

    ,

  • 57

    , , , - , .

    - - , , . , . - . - - .

    - - - - . -, , . , , , - , , - , , -, .

    , , , , , -

    , - - - . - - - - (, ).

    , , . - - , , - , bullying -. - , - . , (.. , , ) , -, .(8)

    - , -

    2000

  • 58 / - 2014

    - - - , .. , . - 2000. - , - - . , - , ,

    , - . - -, - . - - , , , -, . -, - . -,

    . - , , - .(9)

    - , -.

    - , . -

    - -, , . - , , - , - .

    . - .

    ,

  • 59

    . , - .. - . -, , - - .

    , -. - , . , , ,

    - - .

    . . -- - : -, , , - , ; -, , -, - , -

    - ;

    - , - , - , - (, - ..), - -

    .

    - , , - , , - , - . - , , - - .

    1. Economou , Madianos , Theleritis

    C, Peppou L, Stefanis CN. Increased suicidality amid economic crisis in Greece www.thelancet.com Vol 378 October 22, 2011 p. 1459

    2. Alexander Kentikelenis, Marina Karanikolos, Irene Papanicolas, Sanjay Basu, Martin McKee, David Stuckler, "Health effects of financial crisis: omens of a Greek tragedy" Lancet Published Online October 10, 2011 DOI:10.1016/S0140- 6736(11)61556-0

    3. ., . " - ". 48, 54-61, 2011

    4. ., ., - . " - ". 22, 109-119, 2011

    5. ., ., ., - . - , 2010

    6. Triantafyllou K, Chryssi Angeletopoulou IMF and European co-workers attack public health in Greece www.thelancet.com Vol 378 October 22, 2011 p. 1459-1460

    7. Eurochild. How the economic and financial crisis is affecting children & young people in Europe. Report based on evidence collected through Eurochild membership January 2011 www.eurochild.org

    8. ., ., - . (2008). , 4, 10, 44-51

    9. Anagnostopoulos DC, Soumaki E. "The state of child and adolescent psychiatry in Greece during the international financial crisis: a brief report European Child Adolescent" Psychiatry (2013) 22:131134

  • 60

    / - 2014

    15 - 27 , Medochemie Ltd - 10 -

    , European Business Awards, - .

    - -, , , - (, , ).

    100 , - 11 - - , AGETIS. , - - - -

    - , , - Medisyn, 500 800 , - -.

    Medisyn - 19 7 -, - 100. , 520 , 3 - , - 115 - .

    -, . , Medisyn -

    - , claw back rebate - .

    Medisyn - - , - IATRICA A.E., , - , Medisyn, . . , IATRICA 128 , - - Medisyn.

    , , - , Medisyn

    - , .. Medisyn, . . 2013 39%, 8,5 . 2012 11 . .

    Medisyn Roche, Siemens Abbott, , , , - .

    , - , - , - .

    1. Medochemie: 1. Medochemie 60 2. Medisyn 60

    3. AbbVie Running Team 60

    4. strazeneca 62

    5. Galien Think Tank Greece 62

    6. Merck Serono 63

    7. Bayer Algeta 64

    8. Chiesi & 64

    9. Boehringer Ingelheim 66

    10. EKE UCB 68

    11. Roche Diagnostics 68

    12. Novo Nordisk 69

    13. "" Novartis 69

    14. Actelion 70

    15. 70

    16. Ipilimumab 71

    17. Ibrutinib 71

    10

    Medochemie Ltd,

    European Business Awards

    2. Medisyn

  • 61

    3. AbbVie Running Team

    Together We Run, AbbVie Running Team Crohn - , 37 - .

    - - AbbVie, , , - 9 . - - , 20 - , - , 4 Crohn .

    . , . - - . , . - AbbVie Running Team - - , - AbbVie, , . .

    , - - , Medochemie Ltd.

    11 Medochemie Ltd - , , -, 58,4%

    . 630 - 3.800 - 10 -, 1.250 . Medochemie Hellas - .

    1. Medochemie:

  • 62

    / - 2014

    , , , - : , , , -

    , - , - - .

    , , -, - GTTG, -, Prix Galien Greece Galien Think Tank Greece.

    - , , , . , - , .

    , - - , -, . .

    , , - , . .

    , - , - , - , . , - , 1984.

    GTTG - , - .

    5. Galien Think Tank Greece ,

    Galien

    Think Tank Greece

    (GTTG)

    4. Cambridge R&D strazeneca

    Alderley Park, Cheshire -, AstraZeneca Plc, - R&D , - , Cambridge.

    2016. , Alderley Park Manchester Science Parks, - -. - , - 30 50 - .

    , Alderley Park AstraZeneca . , 700 - Cambridge, -.

  • 63

    6. " " Merck Serono

    , , - , -

    MBA . Merck Serono

    30 , -, - , . , - , -, , , -, , - / , - - . - . , - Merck - . -, - 10.000 .

    , - , - 13 18 2014 , . Merck , .

    , . -

    - - Merck, - .

    " " , , , , , Merck Serono

  • 64

    / - 2014

    , - , , - - (pMDI). To

    . , , - Chiesi.

    - - , Chiesi Hellas, . .

    Chiesi

    - , , - , .., . .

    CHIESI Hellas - .

    8. Chiesi Hellas &

    CHIESI Hellas ,

    7. H Bayer Algeta

    Algeta ASA Bayer AG. - , 92% - Algeta.

    Bayer Algeta, 362 - (43 ) - 336 , . Bayer - - -223, 2009. Bayer - 5,5 . , Algeta .

  • 65

  • 66

    / - 2014

    9. : .

    - , - -

    .

    Ashoka, , - - , . - -- (changemakers), .

    - Making more Health, Ashoka Boehringer Ingelheim - , , , - (Making More Health Fellows), , , Frank Hoffmann , - - .

    - , . , -, - , -

    . - .

    Boehringer Ingelheim Ashoka - -, -, : : . (Destination: Change. New Solutions for Greece). - Ashoka, Boehringer Ingelheim .., - (he Hellenic Initiative), - . , SAP Hellas.

    , , , projects , www.changemakers.com/destinationchange 19 2014.

    , - 2014 - , - 2014.

    - (changemakers) - - - , Bill Drayton, - Ashoka.

    , ,

  • 67

    Corp Ad Koropi 210x280 July13 final PRINT.pdf 2 22/7/2013 13:10:39

  • 68

    / - 2014

    UCB 58 , 76 , - -. ,

    , .

    - , 12 ,

    , . - , Global 100 .

    , - HPV, - , - Roche.

    - CINtec Plus, - , .

    -, - (HPV) . , - -

    .

    - HPV - .

    - - , , , . -, Roche Diagnostics. - Roche , , .

    10. UCB:

    20 , ,

    UCB.

    , 18 Global 100 Corporate Knights,

  • 69

    12. Novo Nordisk: vs

    , - , -

    , .

    Novo Nordisk - FDA, -, . , , , . Wall Street Journal, 7 10 -

    , 10 .

    - - GLP-1 ( -1) - 2 . -. - - . -, .

    " "

    Novo Nordisk

    13. Novartis 100 ""

    , Novartis 100 -, , - . Global 100 Most Sustainable Corporations in the World - , . 12 -, - - , CEO , - .

    , Global 100 - , - - .

    Bloomberg, - 350 , - - 4 . - , - , .

  • 70

    / - 2014

    - -, , 13-- - .

    Pfizer, CAPiTA - .

    (CAPiTA), 85.000 -, , , , - .

    , -

    13- - - , (), - . CAPiTA , - -/ - - , .

    CAPiTA, 13- - -

    - - , - Dr William Gruber, Senior Vice President - Pfizer.

    13- - , - - (FDA) , - . , - Pfizer CAPiTA .

    , Clostridium difficile (CDAD),

    FDA, fast track, cadazolid Actelion

    14. Actelion:

    FDA cadazolid - (QIDP), - Actelion Ltd,

    . QIDP cadazolid - - cadazolid , IMPACT . - Fast Track - FDA

    , .

    CDAD - . - , , -. - cadazolid, - Guy Braunstein, MD, - .

  • 71

    16. Ipilimumab

    Bristol-Myers Squibb - , , , .

    ipilimumab .

    - . - , . , - , - , -.

    - - . , -

    - , , -...., .

    ipilimumab - 30 . - - III, ipilimumab - , - ipilimumab 46% 24% , gp100, .

    ipilimumab,

    17. Ibrutinib:

    - (), - , ibrutinib Johnson & Johnson Pharmacyclics Inc FDA.

    - Ibrutinib , - non-Hodgkin.

    - - , Richard Pazdur, - FDA. 2013 15,5 - 4.580 .

  • A

    72 / 2011- 2012

    DNA3 . pi.

    pipi DNA pi. pi pi , . pi . GENESIS Pharma, pi pi . pi . 16 , pi .

    pi www.genesispharma.grGEN

    /KTX

    /FA

    CED

    NA

    /130

    4

    C

    M

    Y

    CM

    MY

    CY

    CMY

    K

    katx_genesis_DNA_half_FACE_210 x280_04.2014_BWP 2014.pdf 1 11/4/2014 5:18:59

  • 73

    Gilead - - -. , - 94% 8

    Sovaldi Wall Street , , 9,1 . . 2017.

    - Merck. 12 - , , - 98% - - .

    , AbbVie Bristol - Myers Squibb 90% .

    , 4 - .

    2013 deal

    4

    C.

    ,

    100%!

  • 74 / - 2014

    , -, - .

    IMS, 2013 - - 4,3% 369,8 , -, 354 10,3% 2,79 . , - .

    : 1. Novartis 8,4%

    235,8 . , 17,3%.2. Pfizer 7,9% 221 . -

    , 10,8%.3. Sanofi 7,1% 199,2 .

    , 14%.4. AstraZeneca 5,7% 158,6 -

    . , 10,9%.5. 5,6% 156,8 .

    , 4,9%. GlaxoSmithKline

    5,3% ( 146,7 . , -4,2%), - E (4,4% 122,1 . , +3%), - (3,8% 105,8 . -, -8,8%), Boehringer Ingelheim (3,6% 99,8 . -, -1,3%) Merck Sharp Dohme (3,3% 91,6 . , -4,6%).

    - 2 . , 20 - 71,2% - . 805 . (28,8% ) - 334 .

    -

    , , Pfizer

    ( 7,9% 29,31 .

    , 1,5%),

    Sanofi (7,2% 26,63 . , +2%), GlaxoSmithKline (7%

    25,83 . , +6,9%), Novartis (6,8% 25,31 . -

    , +1,4%), Bristol Myers Squibb (5,3% 19,63 . , +2%),

    Uni Pharma (5,1% 18,77 . , +6%), AstraZeneca (4,2%

    15,57 . , +6,1%), (4% 14,78 . -

    , +4,8%), Boehringer Ingelheim (3,7% 13,56 . , +4%)

    E (3,5% 12,78 . , +18,3%).

    2013

    Pfizer

    10,3% ,

    4,3%

    - 2013,

    IMS

  • 75

    , : GSK - Novartis 16 . . (14,5 . , 1,5 . ),

    , - Novartis 7,1 . . (5,25 . , 1,8 . - ), - , Novartis - .

    , - , - - joint venture OTC Novartis GSK. Novartis

    36,5% 4 11 .. .

    , Novartis Lilly 4,5 . . Novartis -

    - : - , generics.

    GSK - - 1,3 . , 26.9 . ( pro forma 2013) - . 62%, Consumer Healthcare 24% 14%.

    "" , Novartis, GSK Eli Lilly, ,

    deal

    in brief Novartis; . - GSK - - .

    Novartis - GSK, - , Tafinlar Mekinist, Votrient - .

    , GSK, Novartis, - , - -.

    , GSK - - - Bexsero, - -, Novartis.

    Joint venture 10 . . OTC Novartis Consumer Healthcare GSK - - - , 10 . . OTC -: , - , - .

  • 76 / - 2014

    in brief () , - -, - -, - .

    . - - .

    - (), - (), - 15-52 .

    - , , , .

    - () - - -, -. , -

    . , - (20%-40%) 35% , -. - -

    . - riociguat.

    riociguat - - ,

    / - .

    , , - , - - , - - , .

    - , - PDE5,

    . , - , - .

    , , riociguat, .

    - .

    .. riociguat,

    () .

    2015

  • 77

    3PECIAL2EPORTCLOUD23!#ONFERENCE%UROPE"IG$ATA)43ECURITY

    E'OVERNMENT6)02OUNDTABLEk!k

    "IG$ATA#)/S

    .O

    {

    3TEVE*OBS!PPLE

    WWWBITDAILYGR

    3!36ISUAL!NALYTICS")/!8)3(EALTHCARE

    C

    M

    Y

    CM

    MY

    CY

    CMY

    K

  • 78 / - 2014

    . ,

    ,

    .

    , ,

    ,

    . , ,

    Botox, ,

    ,

    ,

    .

    Botox;

    ! , , - , , .

    , . - , . ,

    - .

    , - - - , , -

    - (University of Wisconsin-

    Madison), 3.8 . . - - , , - - - 6 (, ).

    , - . , -, , -

    , - - .

    , - , ,

    - , - .

    - , - - 20.

    ... !

    , ,

    ,

  • 79

    , - - . , , , -. , - - .

    , , - (80%) -, . , - - .

    , , 11%, - .

    , , -, , - .

    - , - . - 15-20% , 3-5% - 9% - .

    - , - , -, , , .

    -

    , - . - -

    , , , .

    , - -

    , -

    , - .

    !

    - , - . - -3 , , .

    HPV 116 , 12 26 ( - ).

    - , - .

    HPV - . , - - , - - - .

    - -

    - . , - , , . .

    - , - . - ,

    :

    .. -,

    - .

    ! ; , ,

  • 80 / - 2014

    ! Ph.B (Pharma & Health Business)!

    ( )

    &

    (5 ): 40 (10 ): 50 (10 ): 30

    (10 ): 70 (10 ): 90

    ( )

    (10 ): 10

    ( .. 6,5%)

    : (089/470271-92 / IBAN GR46 0110 0890 0000 0894 7027 192)

    ETHOS MEDIA .. . fax 210 998 4953, . .

    -

    *

    *

    ..

    .

    E-MAIL .

    FAX * *

    *

    : , 210 998 4909, [email protected] : ETHOS MEDIA S.A., 29, 174 56 , Fax: 210 998 4953

    Ph.B , , e-mail!

    , . e-book , rich media (video, , flash animations),

    hyperlinks, , ...!

    !

  • 81

  • A

    4 / 2011- 2012

    Veronique Mylan Senior Plant Director( )

    ,

    ,

    .

    Mylan, . , , . .

    Mylan, : .

    : YourMylan.com

    MYL AD_07-12/13

    Mylan Mylan

    Mylan_SP_PH_B_Grece_210x290.indd 1 14-01-20 12:25

    001 EX001 EX20102-0405060708-0910-161718-2930-3738-424344-5152-5960-717273-767778-7980EX Tritiopsthofilo